Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Harvard Business School
Dow
McKesson
Merck

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PALONOSETRON HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Palonosetron Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00306735 Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. Completed Helsinn Healthcare SA Phase 2 2006-03-01 The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
NCT00306735 Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. Completed Eisai Inc. Phase 2 2006-03-01 The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
NCT00343460 APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Completed Heron Therapeutics Phase 3 2006-04-01 RATIONALE: Antiemetic drugs, such as APF530, palonosetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for cancer. It is not yet known whether APF530 is more effective than palonosetron when given together with dexamethasone in preventing nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
NCT00343863 Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer Completed National Cancer Institute (NCI) N/A 2006-01-01 RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer
NCT00343863 Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer Completed University of Washington N/A 2006-01-01 RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Palonosetron Hydrochloride

Condition Name

Condition Name for Palonosetron Hydrochloride
Intervention Trials
Chemotherapy-Induced Nausea and Vomiting 25
Postoperative Nausea and Vomiting 14
Nausea 10
Vomiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Palonosetron Hydrochloride
Intervention Trials
Vomiting 72
Nausea 62
Postoperative Nausea and Vomiting 19
Breast Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Palonosetron Hydrochloride

Trials by Country

Trials by Country for Palonosetron Hydrochloride
Location Trials
United States 216
China 22
Italy 16
Korea, Republic of 13
Russian Federation 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Palonosetron Hydrochloride
Location Trials
Texas 15
Ohio 13
Florida 12
California 10
South Carolina 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Palonosetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Palonosetron Hydrochloride
Clinical Trial Phase Trials
Phase 4 16
Phase 3 26
Phase 2/Phase 3 3
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Palonosetron Hydrochloride
Clinical Trial Phase Trials
Completed 51
Recruiting 20
Not yet recruiting 10
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Palonosetron Hydrochloride

Sponsor Name

Sponsor Name for Palonosetron Hydrochloride
Sponsor Trials
Helsinn Healthcare SA 14
Eisai Inc. 11
National Cancer Institute (NCI) 9
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Palonosetron Hydrochloride
Sponsor Trials
Other 108
Industry 48
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Boehringer Ingelheim
Merck
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.